IDEXX Laboratories, Inc.

NasdaqGS IDXX

IDEXX Laboratories, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: 39.57

IDEXX Laboratories, Inc. Price to Earnings Ratio (P/E) is 39.57 on January 14, 2025, a -22.21% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • IDEXX Laboratories, Inc. 52-week high Price to Earnings Ratio (P/E) is 56.44 on March 01, 2024, which is 42.62% above the current Price to Earnings Ratio (P/E).
  • IDEXX Laboratories, Inc. 52-week low Price to Earnings Ratio (P/E) is 38.26 on January 02, 2025, which is -3.32% below the current Price to Earnings Ratio (P/E).
  • IDEXX Laboratories, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is 47.03.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
NasdaqGS: IDXX

IDEXX Laboratories, Inc.

CEO Mr. Jonathan J. Mazelsky
IPO Date June 21, 1991
Location United States
Headquarters One IDEXX Drive
Employees 11,000
Sector Consumer Staples
Industries
Description

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Similar companies

ICLR

ICON Public Limited Company

USD 200.24

-8.14%

ILMN

Illumina, Inc.

USD 136.48

-5.37%

RVTY

Revvity, Inc.

USD 120.73

-1.61%

IQV

IQVIA Holdings Inc.

USD 197.96

-3.26%

A

Agilent Technologies, Inc.

USD 143.43

1.04%

CRL

Charles River Laboratories International, Inc.

USD 178.08

-6.34%

WAT

Waters Corporation

USD 404.93

1.26%

TMO

Thermo Fisher Scientific Inc.

USD 556.99

0.27%

TWST

Twist Bioscience Corporation

USD 42.75

-1.91%

DHR

Danaher Corporation

USD 237.62

-0.94%

MTD

Mettler-Toledo International Inc.

USD 1.27 K

0.33%

StockViz Staff

January 15, 2025

Any question? Send us an email